macrogol + electrolytes junior eg 6.9 g or. sol. (pwdr.) sachet
eg sa-nv - sodium hydrogen carbonate 89,25 mg; macrogol 6562,5 mg; potassium chloride 23,3 mg; sodium chloride 175,35 mg - powder for oral solution - 6,9 g - sodium bicarbonate 89.25 mg; sodium chloride 175.35 mg; potassium chloride 23.3 mg; macrogol 3350 6562.5 mg - macrogol, combinations
macrogol + electrolytes sandoz 13.125 g - 351 mg - 179 mg - 47 mg or. sol. (pwdr.) sachet
sandoz sa-nv - macrogol 13,125 g; potassium chloride 0,0466 g; sodium chloride 0,3507 g; sodium hydrogen carbonate 0,1785 g - powder for oral solution - 13,125 g - 351 mg - 179 mg - 47 mg - sodium chloride 350.7 mg; sodium bicarbonate 178.5 mg; potassium chloride 46.6 mg; macrogol 3350 13.125 g - macrogol, combinations
potassium chloride tablet, extended release
denton pharma, inc. dba northwind pharmaceuticals - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride extended-release tablets, usp is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene and amiloride. risk summary there are no human data related to use of potassium chloride extended-release tablets, usp during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of
macrogol + electrolytes ab 13.7 g or. sol. (pwdr.) sachet
aurobindo sa-nv - macrogol 13,125 g; potassium chloride 0,0466 g; sodium hydrogen carbonate 0,1785 g; sodium chloride 0,3507 g - powder for oral solution - 13,7 g - macrogol 3350 13.125 g; sodium chloride 0.351 g; potassium chloride 0.047 g; sodium bicarbonate 0.179 g - macrogol, combinations
macrogol ab 4 g or. sol. (pwdr.) sachet
aurobindo sa-nv - macrogol 4000 mg - powder for oral solution in sachet - 4 g - macrogol 4000 4000 mg - macrogol
macrogol ab 10 g or. sol. (pwdr.) sachet
aurobindo sa-nv - macrogol 10000 mg - powder for oral solution in sachet - 10 g - macrogol 4000 10000 mg - macrogol
velmetia 50/850 sitagliptin (as phosphate monohydrate) 50 mg and metformin hydrochloride 850 mg tablet blister pack
merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 850 mg; sitagliptin phosphate monohydrate, quantity: 64.25 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium stearylfumarate; povidone; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - velmetia (sitagliptin phosphate monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see sections 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].
velmetia 50/500 sitagliptin (as phosphate monohydrate) 50 mg and metformin hydrochloride 500 mg tablet blister pack
merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 64.25 mg (equivalent: sitagliptin, qty 50 mg); metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; microcrystalline cellulose; sodium stearylfumarate; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - velmetia (sitagliptin phosphate monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see sections 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].
janumet xr 100/1000 sitagliptin (as phosphate monohydrate)/metformin hydrochloride 100 mg/1000 mg extended release tablet bottle
merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 1000 mg; sitagliptin phosphate monohydrate, quantity: 128.5 mg (equivalent: sitagliptin, qty 100 mg) - tablet, modified release - excipient ingredients: povidone; hypromellose; colloidal anhydrous silica; sodium stearylfumarate; propyl gallate; macrogol 3350; kaolin; carnauba wax; titanium dioxide; hyprolose; indigo carmine aluminium lake - janumet xr (sitagliptin phosphate monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see sections 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].
janumet xr 50/1000 sitagliptin (as phosphate monohydrate)/metformin hydrochloride 50 mg/1000 mg extended release tablet bottle
merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 1000 mg; sitagliptin phosphate monohydrate, quantity: 64.25 mg (equivalent: sitagliptin, qty 50 mg) - tablet, modified release - excipient ingredients: povidone; hypromellose; colloidal anhydrous silica; sodium stearylfumarate; propyl gallate; macrogol 3350; kaolin; carnauba wax; titanium dioxide; hyprolose; iron oxide yellow; indigo carmine aluminium lake - janumet xr (sitagliptin phosphate monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see sections 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].